WHO Launches Global Megatrial of the Four Most Promising Coronavirus Treatments
By News
Published 4 years ago on
March 24, 2020
Share
[aggregation-styles]
Science
Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for the dangerous respiratory disease.
It’s an unprecedented effort—an all-out, coordinated push to collect robust scientific data rapidly during a pandemic. The study, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate.
With about 15% of COVID-19 patients suffering from severe disease and hospitals being overwhelmed, treatments are desperately needed. So rather than coming up with compounds from scratch that may take years to develop and test, researchers and public health agencies are looking to repurpose drugs already approved for other diseases and known to be largely safe.
They’re also looking at unapproved drugs that have performed well in animal studies with the other two deadly coronaviruses, which cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
Read More →
Science
Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for the dangerous respiratory disease.
It’s an unprecedented effort—an all-out, coordinated push to collect robust scientific data rapidly during a pandemic. The study, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate.
With about 15% of COVID-19 patients suffering from severe disease and hospitals being overwhelmed, treatments are desperately needed. So rather than coming up with compounds from scratch that may take years to develop and test, researchers and public health agencies are looking to repurpose drugs already approved for other diseases and known to be largely safe.
They’re also looking at unapproved drugs that have performed well in animal studies with the other two deadly coronaviruses, which cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
Read More →
By Kai Kupferschmidt and Jon Cohen | 22 Mar 2020
RELATED TOPICS:
Google Parent Reports Another Quarter of Robust Growth, Rolls Out First-Ever Quarterly Dividend
Economy /
3 hours ago
US Growth Slows Sharply Amid High Interest Rates and Inflation
Economy /
5 hours ago
Lawyer Says Iran Rapper Famous for Songs After 2022 Killing of Mahsa Amini Sentenced to Death
World /
7 hours ago
Supreme Court Seems Skeptical of Trump’s Claim of Absolute Immunity But Decision’s Timing Is Unclear
Politics /
8 hours ago
Hamas Official: We’ll Put Down Arms if an Independent Palestine Is Created
World /
9 hours ago
Tennessee Lawmakers Pass Bill Criminalizing Adults Assisting Minors in Gender-Affirming Care
NASHVILLE, Tenn. — Tennessee’s GOP-controlled Statehouse on Thursday gave their final approval to legislation criminalizing adults who...
Politics /
3 hours ago
Categories
Latest
Videos
Politics /
3 hours ago
Tennessee Lawmakers Pass Bill Criminalizing Adults Assisting Minors in Gender-Affirming Care
Politics /
3 hours ago
Did Arias ‘Weaponize’ City Attorney’s Office by Requesting Documents from Smittcamp?
Economy /
3 hours ago
Google Parent Reports Another Quarter of Robust Growth, Rolls Out First-Ever Quarterly Dividend
Economy /
5 hours ago